FAQ/Help |
Calendar |
Search |
Today's Posts |
05-24-2013, 07:53 AM | #1 | |||
|
||||
Senior Member
|
Merck Provides Update on Phase III Clinical Program for Preladenant, the Company's Investigational Parkinson's Disease Medicine
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYS: MRK) , ... today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo. http://www.dailyfinance.com/2013/05/...inical-progra/
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
"Thanks for this!" says: | Tupelo3 (05-24-2013) |
05-24-2013, 02:33 PM | #2 | ||
|
|||
Member
|
Once again, positive animal and Phase II early results crumble when the drug goes to Phase III. Too bad.....
|
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
The 5-HT3 receptor antagonist tropisetron | Thoracic Outlet Syndrome | |||
A2a receptor antagonist enters Phase 2b trials | Parkinson's Disease | |||
Phase II trials of A2a receptor antagonists | Parkinson's Disease | |||
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II | Parkinson's Disease |